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Abstract
We present clinical cases, which underline some difficulties in diagnosis and treatment of hepatitis C virus (HCV)
infection. Case report #1 shows a patient who avoided clinical follow-up for HCV until the development of
hepatocellular carcinoma. In this patient, non-invasive procedures did not allow to make a differential diagnosis
between hydatidosis and hepatocellular carcinoma but diagnosis was only made with liver biopsy.
In the case report #2, 24-week treatment with peg-interferon a2 and ribavirin was successfully administered to a
HCV genotype-1b infected patient. Shortening HCV treatment did not impair sustained virological response,
probably because HCV RNA was low (< 200,000 IU/l) at baseline.
Lastly, a case series of patients (#3-6) with hemoglobinopathies is described. Sustained virological response after
peg-interferon a2 and ribavirin was achieved in 2 out of 4 patients. While no severe treatment limiting
hematological effects were encountered, patients needed more frequent blood transfusions. Thus, new anti-HCV
schemes without peg-interferon and ribavirin are urgently needed.
Case report #1 - Hepatocellular carcinoma or
echinococcosis? Considerations from a
challenging case of neglected HCV
Alessio Strazzulla, Giovanni Matera, Selma Valerie
Mammone, Vittoria Vaccaro, Vincenzo Pisani, Chiara
Costa, Francesco Manti, Patrizia Doldo, Maria Carla
Liberto, Aida Giancotti, Carlo Torti, Alfredo Focà
Background
Southern Italy is currently a hyper-endemic area for
hepatitis C virus (HCV) infection. Moreover, it has been
shown that incidence of genotype 4 (gt-4) is increasing
in the Calabria region [1]. These data, however, do not
reflect the actual prevalence of infection, because there
is a large proportion of cases that are not diagnosed or
not retained into care. For 18 years, it has been reported
that chronic HCV infection is one major cause of hepa-
tocellular carcinoma (HCC) [2]. Thus, early diagnosis
and treatment of HCV are important to prevent this
complication. Also, early diagnosis of HCC is important
to better control the disease with a less aggressive ther-
apy than needed if HCC is diagnosed later on.
Echinococcosis is a ubiquitarious, re-emergent zoono-
sis. Its prevalence is high in several areas of the Mediter-
ranean region, including Southern Italy [3]. In Southern
Italy, the major species of medical and public health
concern are Echinococcus granulosus and Echinococcus
multilocularis, which cause cystic echinococcosis and
alveolar echinococcosis, respectively [3]. Hydatid disease
predominantly affects liver and lungs. Both cystic echi-
nococcosis and alveolar echinococcosis are serious dis-
eases with a high fatality rate and poor prognosis if
managed inappropriately [4,5].
Our purpose is to report a case, showing several clinical
features and radiology data, which made differential diag-
nosis between HCC and liver echinococcosis quite
challenging.
Case presentation
A 68 year old male patient born and living in Catanzaro
(Southern Italy) presented with a history of 2-month
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fever, dyspepsia, decreased appetite, weight loss and nic-
turia. Written informed consent to show the data in the
case report was obtained from the patient.
He had been drinking 1 litre of wine daily and smok-
ing 50 cigarettes, but stopped 10 years before. During
the initial consultation the patient denied any chronic
viral infection, including HCV. He suffered from dia-
betes and hypertension, so he was on insulin and anti-
hypertensive therapy. On physical examination, hepato-
megaly was found (stiff hepatic margin at 3 cm below
the costal rim). Blood exams showed low iron levels
(41 µg/dl), high alkaline phosphatase (189 IU/l), moder-
ately raised aspartate aminotransferase (AST) level
(49 IU/l) but normal alanine aminotransferase (ALT)
level (31 IU/l); pseudo-cholinesterase level was 3230 IU/l,
slightly lower than normal values (range 3650-12920 IU/l),
bilirubin, albumin and prothrombin time where within
normal values. White cell count was 9,040 cells/mm3 with
1.1% eosinophils; red cells were 4,610,000/mm3 and hemo-
globin was 12.5 g/dl (cut off < 14 g/dl), platelets, were nor-
mal. Alpha-fetoprotein was mildly elevated at 31.50 ng/ml
(cut off ≤ 8.1). No clinical and hemato-biochemical signs
of cirrhosis were found.
Serology for Salmonella spp. (Widal), Rickettsia spp.
(Weil Felix) and Leishmania spp. (IgG and IgM) were
negative; serology for Brucella spp. showed negative
Wright test and borderline IgG at 12 IU/ml (cut off ≥
12 IU/ml). Echinococcus antibody were at borderline
levels with a serum titer of 1:80 (cut off ≥1:80). Hepatitis
B markers (HBcAb, HBsAg and HBsAb) were all nega-
tive. Investigation of hepatitis C virus (HCV) markers
showed weakly positive HCV-antibodies, HCV-RNA =
131,000 IU/ml), and genotype 1 (gt-1).
The patient, who did not show any previous imaging
exam to compare with, underwent abdominal ultrasound
which revealed “a voluminous cystic mass of 11 × 7 × 9
centimeters at VII and VIII liver segments in the context
of a liver with normal ultrasound structure” and the con-
trast-enhanced ultrasound control described “centripetal
non-homogeneous impregnation of the lesion with slow
and delayed wash out, due to the permanence also in the
late phase (120”) of either hyperechogenicity or hypoe-
chogenicity in each contrast enhanced phase”. Neither
portal vein expansion nor other signs of portal hyperten-
sion were described. This finding suggested a benign
lesion and a hydatid cyst (type 1 of Gharby’s classification
[6]) could not be excluded. Further investigations were
therefore recommended.
A computerized tomography (CT) scan was performed,
showing that lesion was unmodified in size and describing
it as “mixed hypo-isodense with regular borders”, adding
also the description of “enlarged lymphonodes of approxi-
mately 1.5 cm at the hepatic hilum”, and concluding for a
“likely abscessual lesion” (Figure 1). However, this
conclusion did not fit with blood exams, which showed
normal white cell count. Moreover, this finding did not fit
entirely with the typical presentation of HCC at CT, which
usually appear as hypodense and, only in few cases, pre-
sents with a mixed hypo-isodense pattern [7].
Because of inconsistent data, the patient was trans-
ferred in a general surgery ward to perform liver biopsy.
Due to the suspect of echinococcosis, biopsy was pre-
ceded by treatment with albendazole (to avoid perito-
neal dissemination of echinococcus scolices). Notably,
biopsy proved very difficult to perform, due to the pre-
sence of necrotic tissue. Eventually, the histological
exam concluded for hepatocellular carcinoma.
Conclusions
This case highlights the diagnostic difficulties to distin-
guish HCC from other liver lesions. Furthermore, it
shows the importance of an early diagnosis of chronic
HCV in order to prevent severe complications such as
liver cirrhosis and HCC.
Serological markers can be useful to make a differential
diagnosis between echinococcosis and HCC. However, for
echinococcosis, serology can be negative in 10-15 % due
to sequestration of echinococcal antigens inside the cyst,
especially in case of large lesions [6,8]. In our case, the
titer of Echinococcus antibodies (1:80) was borderline, not
confirming or excluding the suspect of hydatid cyst.
Major current guidelines [9-11] suggest that alpha-
fetoprotein is not diagnostic in absence of a typical
Figure 1 Abdominal contrast enhanced CT scan NOTE: CT scan
showed mixed hypo-isodense lesion with regular borders and
enlarged lymphonodes of approximately 1.5 cm at the hepatic
hilum.
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radiological pattern. Moreover, in our case, alpha-feto-
protein was above the normal range but its values were
only mildly elevated (31.50 ng/ml). However, this finding
provided complementary information to imaging, sup-
porting HCC diagnosis especially because the radiological
pattern was inconclusive. Clearly, in such a complicated
case, neither the CT scan or the haemato-biochemical
results (including alpha-fetoprotein) allowed to make the
definitive diagnosis that was obtained only through an
invasive method (liver biopsy).
In conclusion, this case demonstrates that differential
diagnosis between various lesions in the liver may be very
complex and requires invasive techniques. It is therefore
important to provide a timely diagnosis of late complica-
tions and treat them, as soon as possible. Clinical or bio-
chemical features of liver cirrhosis do not necessarily
precede HCC, thus they should not be invariably used to
select most at risk patients. For these reasons, early diag-
nosis, HCV treatment, and retention into care are of out-
standing importance.
Case report #2 - Successful treatment of abbreviated
Peginterferon/ribavirin in a HCV infected patient
with genotype 1b. Could less be more?
Francesco Cesario
Background
Nowadays, three drug regimens which include pegylated
interferon-a2 (PEG-IFN), ribavirin (RBV) and a directly
acting antiviral (DAA), namely boceprevir (BOC) and tela-
previr (TPR), are the gold standard for the treatment of
HCV gt-1 [12,13].
Until 2011, the gold standard was represented by dual
therapy, which included PEG-IFN and RBV. At that time,
the endorsed guidelines indicated that optimal duration
for treatment of gt-1 and gt-4 was 48 weeks, while it was
24 weeks for treatment of gt-2 and gt-3 [14].
We present a case of a patient infected by HCV gt-1
who achieved sustained virological response (SVR) with a
24-week PEG-IFN/RBV treatment. Written informed
consent to show the data in the case report was obtained
from the patient.
Case presentation
In March 2011, a 45 year old HCV gt-1b positive man was
admitted to the Infectious Disease service of the “Annun-
ziata” Hospital of Cosenza (Calabria region) complaining
for high AST and ALT blood levels (2-3 folds higher than
the upper limit of normality) and depression/anxiety. He
was HIV negative, alcohol (>50 gr/day) and drug (heroin
and cocaine) addicted until September 2010. Because of
his depression/anxiety disorder and his drug addiction his-
tory, he was taking citalopram (20 mg/day), lorazepam
(1 mg/ 3 times per day) and methadone (30 mg/day).
On physical examination, hepatomegaly was present
(liver protruding 2 centimeters under the rib edge). Blood
exams showed elevated AST (170 IU/l), ALT (403 IU/l)
and gamma glutamyl transpeptidase (350 IU/l), low albu-
min (1.8 gr/dl) and platelet count (104.000 cel/µl), total
and direct bilirubin were 2.0 and 1.2 mg/dl respectively.
Inflammatory markers were raised (erythrocyte sedimenta-
tion rate 100 mm, C-reactive protein or 40 mg/dl). Ferritin
was 540 ng/ml and hemoglobin was 11 gr/dl. Creatinine
level was elevated at 1.8 mg/dl. Metavir score, estimated
through liver elastography (Fibroscan) [15], was F4
(13.5 KPa). Overall, Child-Pugh score was 7 (Child A).
The patient underwent abdominal ultrasound, which
revealed a slightly enlarged liver and a mass of 5 cm in
the right kidney. Then, an abdominal CT scan described
the renal lesion as “likely malignant”.
In April 2011, the patient underwent right nephrectomy
(Figure 2). A histological exam concluded for granular cell
cancer, which is currently considered a malignant renal
tumor [16]. Further investigations staged the tumor as
T1b-N0-M0, according to the TNM staging system of the
Union for International Cancer Control [17].
In May 2011, notwithstanding negative predictors of
success (such as alcoholism and liver fibrosis), since
HCV-RNA was low (193,873 IU/ml), patient started a
dual therapy with PEG-IFN at a dosage of 1.5 μg/kg per
week (120 µg per week) and RBV (1,000 mg/day). A
rapid virological response (RVR) with HCV RNA unde-
tectable at week 4 was obtained. Thus, considering RVR,
concomitant medications and relevant co-morbidities, a
24-week regimen was preferred rather than the standard
48-week treatment. HCV-RNA was not detectable at
week 12 (extended rapid virological response), 24 (end of
treatment response) and 6 months after the end of
treatment.
Conclusions
In 2011, HCV guidelines suggested that, in patients
infected by gt-1 HCV, duration of treatment could be
shortened in case of RVR and low HCV viral load at base-
line (<200,000 IU/ml) [14,18]. All these characteristics
were present in our case and SVR was actually achieved,
notwithstanding the presence of negative features, such as
important co-morbidities and a difficult to treat genotype.
Interestingly, after achieving RVR, rate of SVR in HCV gt-
1 patients who received a 24 week long PEG-IFN/RBV
treatment was 89% [18]. This case suggests that treatment
duration may vary according to clinical characteristics of
patients and type of virological response.
Case series - Treatment of chronic C hepatitis in
patients affected by hemoglobinopathies. Should
we really improve?
Lucio Cosco, Francesco Quintieri
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Background
Patients affected by hemoglobinopathies, such as thalasse-
mia and sickle cell disease, often develop liver fibrosis due
to high iron levels [19]. Moreover, they have a high risk to
acquire HCV via blood transfusions and this occurrence
may lead to a worsening of the liver disease [20]. For this
reason, treatment of chronic C hepatitis is important, but
it may be less tolerated especially if one considers the risk
of anaemia.
Case presentations
We present a brief case series of patients (Table 1) affected
by hemoglobinopathies who underwent treatment with
PEG-IFN and RBV at the Infectious Diseases Service of
Hospital “Pugliese-Ciaccio” in Catanzaro. Written
informed consent to show the data in this case series was
obtained from all patients.
a) Case #3 - In October 2010, a 35 year old woman
was admitted to the “Pugliese-Ciaccio” Hospital to
start HCV treatment. She was affected by thalassemia
major and she knew to be HCV positive since 1990.
She had HCV-RNA of 3,590,000 IU/l and gt-2a. ALT
was 112 IU/l and hemoglobin was 10.1 g/dl. Liver
Metavir score, estimated via transient elastography
(Fibroscan™) [15], was F2. She started a 24-week
treatment with PEG-IFNa2b (100 µg per week) and
RBV (800 mg/day). RBV dosage was maintained until
the end of treatment. Next controls showed not
detectable HCV-RNA at weeks 4, 12 and 24. ALT
decreased to 61 IU/ml by week 4, while it was normal
at week 24. After 2 years, HCV-RNA was still not
detectable (SVR) and ALT was normal. The patient
was also treated with blood transfusions, which
increased from a transfusion/month before HCV treat-
ment to a transfusion/10 days during PEG-IFN/RBV
therapy. No hemolytic crisis occurred.
b) Case #4 - In November 2011, a 38 year old, HCV
positive and thalassemic (thalassemia major) man
started therapy with PEG-IFNa2a (180 µg per week)
and RBV (800 mg/day). His history of HCV had
started in 1991. He was infected by HCV gt-4 and, at
baseline, HCV-RNA was 18,900,000 IU/l. Moderate
fibrosis resulted from liver elastography (7.9 KPa) with
an estimated Metavir Score of F2 [15]. Blood exams
showed anaemia (hemoglobin 8.9 g/dl). The scheduled
duration of treatment was 48 weeks but, unfortunately,
treatment was stopped at week 24 because of non
response. Indeed, HCV-RNA was detectable at week 4
(3810 IU/l), 12 (3830 IU/l) and 24 (21,900 IU/l).
Dosage of RBV was kept at 800 mg/day and no severe
hemolysis occurred. After 7 months from the suspen-
sion of therapy, viral load was 3,350,000 IU/l. During
treatment, the patient received an higher number of
blood transfusions (a transfusion/2 weeks) than before
treatment (around a transfusion/3 weeks).
c) Case #5 - In December 2011, a 31 year old man
came to the Infectious Diseases Service of Hospital
“Pugliese-Ciaccio” to start HCV treatment. He was
affected by drepanocytosis (sickle cell disease) and
infected by HCV gt -1b since 1990. At baseline,
HCV-RNA was 745,000 IU/l. Mild chronic hepatitis
was revealed by liver biopsy (Metavir score F2). ALT
was twofold the normal value and hemoglobin was
8.3 g/dl. He underwent a 18 month long therapy,
from December 2011 to June 2013, with PEG-
IFNa2b (100 µg per week) and RBV (800 mg/day).
HCV-RNA was 34,470 IU/l at week 12 and it became
not detectable at week 24. At end of treatment HCV-
RNA was not detectable and ALT was normal. Due
to the absence of severe hemolytic crisis, increasing
the number of blood transfusions (from 1/3 weeks to
1/10 days ) was the only intervention required to
manage anaemia, without any needs to reduce RBV.
d) Case #6 - In March 2012, a 42 year old woman
started PEG-IFN/RBV therapy. She was affected by
thalassemia major and she knew to be HCV gt-2a
positive since 1991. Blood exams showed anaemia
(hemoglobin 8.9 g/dl) and elevated ALT (106 IU/l).
The HCV viral load was 3,430,000 IU/l. Liver stiff-
ness (assessed through Fibroscan™) was 8.5 KPa
(Metavir score F2) [15]. She followed treatment for
24 weeks with PEG-IFNa2b (100 µg per week) and
RBV (800 mg/day). She reached RVR and end of
treatment response, included the normalization of
ALT. Unfortunately, 5 months after the end of ther-
apy, she relapsed (HCV-RNA 1,360,000 IU/l). Blood
transfusions were performed during treatment more
frequently than before therapy (from a transfusion/3
weeks to a transfusion/week). However, reduction of
RBV was not necessary and hemolytic crisis did not
appear during PEG-IFN/RBV.
Conclusions
Patients with hemoglobinopathies often exhibit signifi-
cant liver fibrosis [19]. However, in all of our cases, liver
disease, estimated through liver elastography, was mod-
erate (corresponding to F2 at Metavir score). It has to
be seen whether elastography is an accurate method to
estimate fibrosis in presence of liver damage associated
with hemoglobinopathies beside HCV. Interestingly,
before HCV treatment, all patients presented with high
ALT levels that normalized by the end of treatment.
This suggests that, in case of moderate fibrosis, HCV
treatment reduces liver inflammation even when SVR is
not achieved.
Anaemia is the most common side effect of PEG-IFN/
RBV and patients with hemoglobinopathies require a
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higher number of blood transfusions when they are treated
with PEG-IFN/RBV [21]. Indeed, in our short case series,
all patients needed more blood transfusions to overcome
reduction of hemoglobin. Moreover, anaemia is the most
common side effect of DAAs, which represent the current
gold standard for treatment of gt-1 HCV in association
with PEG-IFN/RBV. Due to the elevated risk of severe
anaemia, current available triple therapy with PEG-IFN/
RBV/DAA may be difficult to apply in these patients. Con-
sequently, we are looking forward to the next generation
DAAs, which are expected to be strongly effective even in
absence of PEG-IFN and RBV.
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